Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide in Children With Hypochondroplasia
NCT07073014Phase 3Enrolling by invitation
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Oct 2044
- Modality
- Peptides
- Countries
- 9
01
Overview
A Phase 3 trial of vosoritide in hypochondroplasia (HCH), sponsored by BioMarin Pharmaceutical. Started Jun 2025; status: enrolling by invitation.
02
Drugs
vosoritide
03
Conditions
hypochondroplasia (HCH)
Beyond the preview
Go deeper on NCT07073014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07073014.